

## Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study

TIMNA NAFTALI,\* LIHI BAR-LEV SCHLEIDER,<sup>†</sup> IRIS DOTAN,<sup>§</sup> EPHRAIM PHILIP LANSKY,<sup>||</sup> FABIANA SKLEROVSKY BENJAMINOV,\* and FRED MEIR KONIKOFF\*

\*Department of Gastroenterology and Hepatology, Meir Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba; <sup>†</sup>Tikun Olam for Promotion of Medical Cannabis, Tel Aviv; <sup>§</sup>IBD Center, Department of Gastroenterology, Sourasky Medical Center, Tel Aviv; and <sup>||</sup>Laboratory of Applied Metabolomics and Pharmacognosy, Institute of Evolution, University of Haifa, Haifa, Israel

**BACKGROUND & AIMS:** The marijuana plant *Cannabis sativa* has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but this has not been investigated in controlled trials. We performed a prospective trial to determine whether cannabis can induce remission in patients with Crohn's disease.

**METHODS:** We studied 21 patients (mean age, 40 ± 14 y; 13 men) with Crohn's Disease Activity Index (CDAI) scores greater than 200 who did not respond to therapy with steroids, immunomodulators, or anti-tumor necrosis factor- $\alpha$  agents. Patients were assigned randomly to groups given cannabis, twice daily, in the form of cigarettes containing 115 mg of  $\Delta$ 9-tetrahydrocannabinol (THC) or placebo containing cannabis flowers from which the THC had been extracted. Disease activity and laboratory tests were assessed during 8 weeks of treatment and 2 weeks thereafter.

**RESULTS:** Complete remission (CDAI score, <150) was achieved by 5 of 11 subjects in the cannabis group (45%) and 1 of 10 in the placebo group (10%;  $P = .43$ ). A clinical response (decrease in CDAI score of >100) was observed in 10 of 11 subjects in the cannabis group (90%; from 330 ± 105 to 152 ± 109) and 4 of 10 in the placebo group (40%; from 373 ± 94 to 306 ± 143;  $P = .028$ ). Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.

**CONCLUSIONS:** Although the primary end point of the study (induction of remission) was not achieved, a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects. Further studies, with larger patient groups and a nonsmoking mode of intake, are warranted. [ClinicalTrials.gov](http://ClinicalTrials.gov), NCT01040910.

**Keywords:** Inflammatory Bowel Disease; Crohn's Disease; Cannabinoids; Endocannabinoid; Inflammation.

A part from its recreational properties, the marijuana plant cannabis has been used for centuries as a medicinal treatment for a variety of ailments. The cannabis plant contains more than 60 different compounds, collectively referred to as *cannabinoids*.<sup>1</sup> Although  $\Delta$ 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) seem to be most active, other as yet unknown ingredients also may have beneficial effects.

Cannabinoids have a profound anti-inflammatory effect, mainly through the cannabinoid 2 receptor, although cell-mediated immunity was found to be decreased in chronic marijuana users.<sup>2</sup> A potent anti-inflammatory effect of cannabis was observed in rats.<sup>3</sup> Almost all major immune modulation events involve the endocannabinoid system. Cannabinoids shift the balance of proinflammatory cytokines and anti-inflammatory cytokines toward a T-helper cell type 2 profile (Th2 phenotype), and suppress cell-mediated immunity, whereas humoral immunity may be enhanced.<sup>4</sup> Cannabinoid exposure antagonizes release of prostaglandins, histamine, and the matrix-active proteases from mast cells.<sup>5</sup> The phagocytic function of macrophages is suppressed by cannabinoid

exposure. Cannabinoids also suppress inflammation at a secondary, chronic level by down-regulating the production of cytokines such as tumor necrosis factor (TNF)- $\alpha$ , interferon- $\gamma$ , and interleukin-1.<sup>6</sup> They therefore may be beneficial in inflammatory conditions.

Within gastroenterology, cannabis has been used to treat anorexia, emesis, abdominal pain, gastroenteritis, diarrhea, intestinal inflammation, and diabetic gastroparesis.<sup>7</sup> Cannabinoids were found to ameliorate inflammation in a mouse model of colitis.<sup>8</sup> In 2,4,6-trinitrobenzene sulfonic acid-induced colitis, cannabinoids decreased macroscopic inflammation,

**Abbreviations used in this paper:** CBD, cannabidiol; CDAI, Crohn's Disease Activity Index; CRP, C-reactive protein; IBD, inflammatory bowel disease; SF-36, Short-Form 36; THC,  $\Delta$ 9-tetrahydrocannabinol; TNF, tumor necrosis factor.

© 2013 by the AGA Institute  
1542-3665/\$36.00

<http://dx.doi.org/10.1016/j.cgh.2013.04.034>

myeloperoxidase activity, and peristalsis.<sup>9</sup> The combination of THC and CBD was more effective than either substance alone.<sup>10</sup>

In a retrospective observational study, we recently reported that cannabis had beneficial effects in Crohn's disease.<sup>11</sup> However, to date, no placebo-controlled trials have been published on the use of cannabis in inflammatory bowel disease (IBD). We conducted a double-blind, placebo-controlled study to investigate the effects of cannabis on patients with active Crohn's disease.

### Materials and Methods

The primary objective of the study was the induction of remission, defined as a Crohn's Disease Activity Index (CDAI) score of 150 or less after 8 weeks of cannabis treatment. Secondary objectives were response rate, determined as a 100-point reduction of CDAI, a reduction of at least 0.5 mg in C-reactive protein (CRP), or improvement in quality of life of at least 50 points, as measured by the Short-Form 36 (SF-36) health survey.

Patients with an established diagnosis of Crohn's disease who were referred to the Gastroenterology Institute at Meir Medical Center, a tertiary-care facility, between September 2010 and September 2011 were screened for eligibility. Eligible patients were at least 20 years of age and had active Crohn's disease, with a calculated CDAI score between 200 and 450 points. All patients had failed at least one form of medical treatment for the disease, including mesalamine, corticosteroids, thiopurines, methotrexate, or anti-TNF- $\alpha$ . Patients receiving corticosteroids were on a stable dose for at least 1 month, and those receiving thiopurines were on a stable dose for at least 3 months. Anti-TNF- $\alpha$  failure was declared after at least 4 doses. Patients with short-bowel syndrome, symptomatic stricture, abscess, abdominal surgery within the previous 3 months, pregnancy or intention to become pregnant within 6 months, a history of mental illness, drug abuse, or previous cannabis consumption were excluded. Patients also were excluded if in their physician's judgment they might be vulnerable to drug addiction or mental instability. The study protocol was approved by the institutional ethics committee. All patients provided written informed consent before enrollment. All co-authors had access to the study data and reviewed and approved the final manuscript.

By using the block method<sup>12</sup> in a 1:1 ratio, patients were assigned randomly to receive either medical cannabis or placebo in the form of cigarettes. Both patients and investigators were blinded to the treatment group assignment. Each cigarette contained 0.5 g of dried cannabis flowers (flowers have a higher THC content than leaves), corresponding to 115 mg THC. The active cannabis was made from dried flowers of genetically identical plants of *Cannabis sativa* Variety Indica Erez (courtesy of Tikun Olam, Ltd, Tel Aviv, Israel), known to contain 23% THC and less than 0.5% CBD. The placebo was made of cannabis flowers from which THC had been extracted. Dried flowers of Cannabis were mixed with 95% ethanol (food grade) and sat in a clean glass jar for 2 weeks. The alcohol then was decanted and fresh 95% ethanol was added to the jar. This procedure was repeated 3 times. After this, the flowers were covered with a mixture of spirits comprising the first distillate head fraction from a proprietary mixture of organically grown pomegranate (*Punica granatum*) juice, pericarps, leaves, and flowers that had been allowed to ferment to completion (~2 wk) in the presence of 0.025% *Saccharomyces cerevisiae* Var. 18 (courtesy of Rimonest, Ltd, Haifa, Israel). After 3 more days, the spirits were decanted

and the flowers were allowed to dry in ambient air with ventilation for 72 hours. The final product was tested for cannabinoids and shown to contain less than 0.4% THC and undetectable amounts of all other cannabinoids including CBD. The process was repeated and shown to be reproducible. All cigarettes were machine made to ensure they were identical.

Patients were followed up for 8 weeks of treatment and 2 additional weeks of a wash-out period. Concomitant medications remained constant throughout the study except for corticosteroids, which were tapered when possible. Patients were evaluated at weeks 0, 2, 8, and 10 including medical interview, physical examination, assessment of disease activity (CDAI), and blood tests (complete blood count, liver and kidney function, and CRP). Quality of life (SF-36) and side-effect questionnaires were completed at weeks 0 and 8. The side-effect questionnaire included questions about changes in ability to concentrate, work, sleep, abdominal pain, appetite, general well being, and general satisfaction with the treatment. Relevant symptoms of drug addiction as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition,<sup>13</sup> included cravings for a larger dose and ability to continue regular activities, such as work and studies. Answers were graded by severity from 1 to 7.

### Statistical Analyses


Numeric results are presented as mean  $\pm$  standard deviation, and categorical results are shown in percentages. The difference in CDAI between the 2 groups (study vs control) was examined. The change (delta) in CDAI between the baseline measurement and after 8 weeks of study was calculated and the mean delta was compared between the 2 groups using the *t* test for independent groups. In addition, the performance of each group (ie, the change per group) also was examined by applying the *t* test for paired groups for the study and control groups separately. For categorical measurements, the chi-square and the Fisher exact tests were used to compare the groups at each time point. The delta SF-36 between the baseline measurement and after 8 weeks of study was calculated and the mean delta was

**Table 1.** Demographic Data

Variable	Study group (N = 11)	Placebo group (N = 10)	P value
Age	46 $\pm$ 17	37 $\pm$ 11	.02
Male	6 (54%)	6 (60%)	.57
Family history of IBD	5 (45%)	5 (50%)	1
Current tobacco smoking	2 (18%)	3 (30%)	.65
Time since diagnosis of Crohn's disease, y	18 $\pm$ 14	15 $\pm$ 8	.797
Involved segment of intestine <sup>a</sup>			
Terminal ileum	8 (72%)	5 (50%)	.38
Colon	4 (36%)	4 (40%)	.6
Other part of small intestine	3 (27%)	2 (20%)	1
Disease phenotype			
Luminal	36% (4)	60% (6)	.39
Fistulizing	45% (5)	20% (2)	.36
Strictureing	18% (2)	20% (2)	1
Past surgery			
Resection of terminal ileum	45% (5)	60% (6)	.66
Partial colectomy	9% (1)	10% (1)	.7
Adhesiolysis	9% (1)	0% (0)	1

NOTE. Mean  $\pm$  standard deviation, n (%) shown.

<sup>a</sup>One patient might have had involvement of more than 1 segment.



**Figure 1.** CDAI scores in study and placebo groups before and after treatment.

compared between the 2 groups using the *t* test for independent groups. In addition, the difference in side effects between the 2 subgroups was examined. Because the measurements were ordered, the Mann–Whitney nonparametric test for independent groups was used. All statistical analyses were performed using the statistical software package SPSS, version 20 (SPSS Inc, Chicago, IL).

**Results**

Of 51 patients screened, 29 did not meet the inclusion criteria: 15 patients had a CDAI less than 200, 7 patients did not consent, 1 patient was diagnosed with ulcerative colitis, 3 patients were designated for surgery (1 because of stricture of the small bowel and 2 because of an intra-abdominal abscess), and 3 patients already were receiving medical cannabis. Twenty-two eligible patients were recruited. One patient withdrew consent before consumption of the study drug and another patient withdrew after 2 weeks of treatment. The second patient was included in the analysis. Thus, 21 patients, 11 in the study group and 10 in the placebo group, completed the study (Supplementary Figure 1). Demographic details of the patients are listed in Table 1. In the study group, 1 patient had a permanent pacemaker, 1 patient had type 2 diabetes, and 1 patient had thalassemia minor. One patient in the placebo group had glaucoma. All other patients were healthy, except for Crohn’s disease.

Twenty patients had been treated with thiopurines and 18 patients had been treated with anti-TNF-α in the past. Of the 18 patients treated with anti-TNF-α, 5 patients had to stop treatment because of a severe allergic reaction, 4 patients were still receiving anti-TNF-α, 7 patients did not respond or lost response

after at least a full induction dose, 1 patient stopped treatment despite it being effective, and 1 patients stopped treatment owing to pneumonia. At the time of the study, 4 patients (3 in the study group and 1 in the placebo group) were steroid dependent (Table 2). One patient received prednisone 20 mg for 2 years, 1 patient received prednisone 35 mg for 6 months, and 2 patients received budesonide 9 mg for 2 and 3 years each. They all relapsed as soon as they tried to stop the steroids. In patients who had undergone surgery, time from previous surgery to the study was on average 6 years (range, 1–30 y).

Five patients (45%) in the study group and 1 patient (10%) in the placebo group achieved full remission, with a CDAI of 150 or less (Figure 1). This difference did not reach statistical significance (*P* = .43), possibly because of the small sample size. Before treatment, the mean CDAI was 330 ± 105 and 373 ± 94 in the study and placebo groups, respectively (*P* = .3). After 8 weeks of treatment, the CDAI decreased to 152 ± 109 in the study group, and 306 ± 143 in the placebo group (*P* between groups < .05). The response rate (ie, CDAI reduction of >100 points) was 90% (10 of 11) in the study group, whereas in the placebo group the CDAI increased in 3 (30%) patients, decreased by less than 100 points in 3 (30%) patients, and decreased by more than 100 points in 4 (40%) patients (Figure 2). The mean reduction in CDAI was 177 ± 80 in the study group and 66 ± 98 in the placebo group (*P* = .005). Two weeks after cannabis treatment was stopped, the mean CDAI in the study and placebo groups was 331 ± 155 and 280 ± 61, respectively (*P* = .43; Figure 1).

Four patients in the placebo group (but none in the cannabis group) deteriorated and needed rescue intervention during the study period. Three of these 4 patients stopped taking their assigned study treatment (ie, stopped smoking the placebo cigarettes) because they believed it was not helping them. Three steroid-dependent patients in the cannabis group stopped steroids during the study. Thus, at the end of the study no patient in the cannabis group required steroids. Two patients in the study group, who were treated with opiates owing to severe chronic abdominal pain, stopped opiates during the study.

A significant increase in quality of life as assessed by SF-36 was observed in the cannabis group (from 68 at week 0 to 86 after 8 weeks of treatment; *P* = .05), although no effect was observed in the placebo group (SF-36, 71 vs 79; *P* = .5). The delta of SF-36 between the baseline measurement and after 8 weeks was +28 and +5 in the study and placebo groups, respectively (*P* = .04). There were no significant changes in blood count, CRP, or liver and kidney function during the study (Table 3). CRP before treatment was 1.4 ± 2 mg/dL and 2.6 ± 2.5 mg/dL (normal, <0.5 mg/dL) in the cannabis and placebo groups, respectively (*P* = .1). A decrease in CRP of more than 0.5 mg/dL from week 0 to week 8 was observed in 3 patients in the study group and 2 patients in the placebo group (*P* = .43).

**Table 2.** Past and Current Medical Treatment

Medication	Past medication, n (%)			Concomitant medication, n (%)		
	Study (N = 11)	Placebo (N = 10)	<i>P</i> value	Study (N = 11)	Placebo (N = 10)	<i>P</i> value
Mesalamine	11 (100)	10 (100)	NS	2 (218)	2 (20)	.7
Steroids	11 (100)	9 (90)	.4	4 (36) (3 steroid dependent)	2 (20) (1 steroid dependent)	.9
Purine analog	10 (90)	10 (100)	NS	2 (27)	6 (60)	.9
Methotrexate	3 (27)	1 (10)	.9	1 (9)	0	1
Anti-TNF-α	9 (81)	8 (80)	.7	1 (9)	4 (40)	.9

NS, not significant.

**Table 3.** Laboratory Tests

Test	Study (N = 11)			Placebo (N = 10)		
	Start	End	P value	Start	End	P value
Hemoglobin level, g/dL	12.8 ± 1	13.0 ± 1.3	.3	12 ± 1	12 ± 2	.6
Hematocrit, %	39.4 ± 3	35.1 ± 4	.3	38 ± 5	37 ± 6	.6
White blood cell count, K/ $\mu$ L	8 ± 3	8.2 ± 3	.9	6.1 ± 2	5.7 ± 2	.7
CRP, mg/dL	1.44 ± 2	0.99 ± 0.9	.4	2.6 ± 2.5	1.7 ± 0.7	.2

There was no difference between study and placebo groups in side effects, including sleepiness, nausea, and confusion. However, the study group reported significantly less pain, improved appetite, and a higher satisfaction from the treatment (Table 4). Patients denied any withdrawal symptoms when stopping cannabis use at the end of the study. Blinding assessment was performed at the end of the study for each patient. Except for 2 patients in the placebo group, all other patients were able to tell correctly whether they were receiving cannabis or placebo.

**Discussion**

Although a significant body of work suggests that cannabinoids suppress inflammation<sup>14</sup> and many patients with IBD self-medicate with cannabis, there are no placebo-controlled trials assessing its efficacy in inflammatory disease. This might be owing to reluctance to use an illegal drug. This was a placebo-controlled trial to critically assess cannabis use for treating Crohn's disease.

The primary end point of this study was induction of remission. Although 5 patients in the study group and 1 patient in the placebo group entered clinical remission, the difference did not reach statistical significance, possibly because of the small sample size. However, our data showed that 8 weeks of treatment with THC-rich cannabis, but not placebo, was associated with a significant decrease of 100 points in CDAI scores.

In this trial, cannabis induced clinical remission in 50% of patients. Taking into account that our participants had long-standing Crohn's disease, with 80% nonresponse or intolerance to anti-TNF- $\alpha$ , this result is impressive. In this trial, the observed improvement was solely symptomatic, with no objective evidence of reduction in inflammatory activity. In addition, patients relapsed 2 weeks after cannabis treatment was stopped. Therefore, based on the available data, one cannot argue that cannabis is a

successful treatment for the inflammatory process in Crohn's disease. Thus, until further studies are conducted, cannabis should be reserved for compassionate use only in patients who have exhausted all other medical and surgical options.


Because this was a pilot study, probable efficacy data were unavailable, therefore power calculation could be based on estimation only. With a significance level of 5% and a power of 80% to detect a significant difference of 100 points in CDAI, we would need a sample size of 12 patients in each group, or a total of 24 patients.

Herbal preparations present problems in measuring the contribution of each constituent of a mixture. Thus, mistakes can be made in using nonstandardized extracts for clinical testing. We dealt with this problem by using cannabis made from genetically identical plants grown from twigs of the same mother plant and in equal conditions. Plants were tested to verify an equal content of active ingredients. We also standardized the machine-made cigarettes to contain equal weights of cannabis flowers.


**Table 4.** Side Effects

	Placebo median (minimum–maximum)	Cannabis median (minimum–maximum)	P value
<b>Negative side effects<sup>a</sup></b>			
Sleepiness	4 (3–4)	3 (1–6)	.5
Nausea	4 (3–4)	4 (1–4)	.3
Concentration	4 (4–5)	4 (4–7)	.3
Memory loss	4 (4–4)	4 (4–6)	.4
Confusion	2 (2–2)	2 (1–2)	.4
Dizziness	2 (1–2)	2 (1–2)	.9
<b>Positive side effects<sup>b</sup></b>			
Pain	4 (3–4)	1 (1–2)	.001
Appetite	4 (4–4)	2 (1–4)	.008
Satisfaction	7 (3–7)	1 (1–4)	.002

<sup>a</sup>On a scale from 1 to 7, where 1 = no effect; 7 = very strong effect.  
<sup>b</sup>On a scale from 1 to 7, where 1 = very satisfied; 7 = very dissatisfied.



**Study group**



**Placebo group**

**Figure 2.** CDAI scores of individual patients in study and placebo groups before and after treatment.

Although this was a placebo-controlled trial, complete blinding of patients was not easy to achieve because of possible psychotropic effects. We tried to minimize this limitation by recruiting only patients naive to cannabinoids. However, at the end of the study period, most of the subjects were able to tell correctly whether they were receiving the study drug or placebo. Future studies with oral administration may overcome this problem due to slower absorption.

In this study, we chose to administer cannabis by smoking because this route induces a rapid increase in blood cannabinoid levels.<sup>15</sup> During smoking, the acids are decarboxylated to the active free cannabinoids, which may explain why ingesting cannabis orally is less effective than smoking.<sup>16</sup> Nevertheless, because of the known harmful effects of smoking on the lungs, the efficacy and safety of oral cannabis should be investigated further.

There is an understandable restraint in the medical community regarding the use of cannabis, which is an illegal drug in most countries. Yet, cannabis has a remarkably good safety profile.<sup>17,18</sup> In this study, during short-term use of 8 weeks, we did not observe any significant side effects. All patients continued normal function and did not report significant differences in behavioral parameters such as concentration, memory, or confusion. Indeed, it is known that tolerance to the central effect of cannabis develops after 12 days of use.<sup>19</sup> When requested to stop cannabis after 8 weeks, none of the patients experienced difficulty or withdrawal symptoms. All patients in the study group expressed strong satisfaction with their treatment and improvement in their daily function. It should be noted, however, that our patients were treated for only a short period. It is well known that cannabis dependence exists and patients might have difficulty weaning after prolonged cannabis use, even when the IBD is in complete remission. Therefore, until further data are available, long-term medical cannabis cannot be recommended. Although the long-term side effects of cannabis are not negligible, other treatments for Crohn's disease, such as steroids, purine analogs, or anti-TNF- $\alpha$ , also carry the risk of significant side effects, some even life-threatening. Additional studies will be needed before the exact effect of cannabis in IBD, whether anti-inflammatory or only symptomatic, can be determined. However, the potential benefits should not be ignored only because of concern for possible side effects. Taking into account that Crohn's disease is a chronic debilitating disease that sometimes severely may compromise patients' quality of life, the ability to provide symptomatic relief judiciously, in carefully selected patients, should not be overlooked.

In summary, in this controlled pilot study, cannabis treatment was not superior to placebo in induction of remission. However, cannabis provided a significantly higher rate of clinical response without any alarming side effects. The strain of cannabis used was specifically rich in THC, but other cannabinoids may be beneficial as well. Future larger controlled studies should look into the role of cannabinoids in controlling inflammation and symptoms in IBD.

## Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at [www.cghjournal.org](http://www.cghjournal.org), and at <http://dx.doi.org/10.1016/j.cgh.2013.04.034>.

## References


- Hall W, Solowij N. Adverse effects of cannabis. *Lancet* 1998; 352:1611–1616.
- Nahas G, Succi-Foca N, Armand JP. Decrease of cellular immunity in hashish (marihuana) smokers. *C R Acad Sci Hebd Seances Acad Sci D* 1973;277:979–980.
- Sofia RD, Knobloch LC, Vassar HB. The anti-edema activity of various naturally occurring cannabinoids. *Res Commun Chem Pathol Pharmacol* 1973;6:909–918.
- Pacifici R, Zuccaro P, Pichini S, et al. Modulation of the immune system in cannabis users. *JAMA* 2003;289:1929–1931.
- Small-Howard AL, Shimoda LM, Adra CN, et al. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. *Biochem J* 2005;25:25.
- Berdyshev EV. Cannabinoid receptors and the regulation of immune response. *Chem Phys Lipids* 2000;108:169–190.
- Izzo AA, Camilleri M. Gastrointestinal and liver diseases: basic and clinical aspects: emerging role of cannabinoids. *Gut* 2008; 57:1140–1155.
- Storr MA, Keenan CM, Zhang H, et al. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. *Inflamm Bowel Dis* 2009;11:1678–1685.
- Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant *Cannabis sativa*, is protective in a murine model of colitis. *Mol Med* 2009;87: 1111–1121.
- Jamontt JM, Molleman A, Pertwee RG, et al. The effects of D9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. *Br J Pharmacol* 2010;160:712–723.
- Naftali T, Bar Lev L, Yablekovitch D, et al. Treatment of Crohn's disease with cannabis: an observational study. *Isr Med Assoc J* 2011;13:455–458.
- Altman DG, Bland JM. How to randomise. *BMJ* 1999;319:703–704.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:215–223.
- Greineisen WE, Turner H. Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. *Int Immunopharmacol* 2010; 10:547–555.
- Williamson EM, Evans FJ. Cannabinoids in clinical practice. *Drugs* 2000;60:1303–1314.
- Schon F, Hart P, Hodgson TR, et al. Suppression of pendular nystagmus by cannabis in a patient with multiple sclerosis. *Neurology* 1999;53:2209–2210.
- Gurley RJ, Aranow R, Katz M. Medicinal marijuana: a review. *J Psychoactive Drugs* 1998;30:137–147.
- Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. *CMAJ* 2008;178:1669–1678.
- Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. *Ann N Y Acad Sci* 1976;282: 221–239.

## Reprint requests

Address requests for reprints to: Timna Naftali, MD, Institute of Gastroenterology and Hepatology, Meir Hospital, Kfar Saba 44281, Israel. e-mail: [naftali@post.tau.ac.il](mailto:naftali@post.tau.ac.il); fax: (972) 9-7441731.

## Conflicts of interest

This author discloses the following: Lihi Bar-Lev Schleider is an employee of Tikun Olam organization, which supplied the cannabis and placebo for the research. The remaining authors disclose no conflicts.



Supplementary Figure 1. CONSORT flow diagram.